P2Y12-话题@MedSci - 梅斯（MedSci）

#P2Y12#

28篇内容 | 1570人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1940209, encodeId=b66e1940209af, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识, objectType=article, longId=124756, objectId=eba3124e5682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba3124e5682, replyNumber=0, likeNumber=66, createdTime=2018-03-04, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba3124e5682, moduleTitle=Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=eba3124e5682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940207, encodeId=5ab7194020e63, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？, objectType=article, longId=120654, objectId=cd061206549f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd061206549f, replyNumber=0, likeNumber=77, createdTime=2018-06-08, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd061206549f, moduleTitle=【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cd061206549f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940205, encodeId=e4b61940205e6, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Am Heart J：血小板功能检测如何指导P2Y12受体抑制剂治疗选择？, objectType=article, longId=101658, objectId=ebbe1016584f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebbe1016584f, replyNumber=0, likeNumber=78, createdTime=2018-04-29, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebbe1016584f, moduleTitle=Am Heart J：血小板功能检测如何指导P2Y12受体抑制剂治疗选择？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ebbe1016584f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940208, encodeId=0e1f19402084d, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微, objectType=article, longId=120661, objectId=dcc912066195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcc912066195, replyNumber=0, likeNumber=74, createdTime=2018-01-01, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcc912066195, moduleTitle=【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dcc912066195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940206, encodeId=214319402068c, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Circulation：糖尿病患者血小板表达活化的P2Y12受体, objectType=article, longId=103280, objectId=2f82103280eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f82103280eb, replyNumber=0, likeNumber=54, createdTime=2017-09-03, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f82103280eb, moduleTitle=Circulation：糖尿病患者血小板表达活化的P2Y12受体, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2f82103280eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940204, encodeId=feb419402041c, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Lancet：急性冠脉综合征临床显著出血：P2Y12抑制剂+利伐沙班vs阿司匹林, objectType=article, longId=99395, objectId=1a2d99395a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2d99395a3, replyNumber=0, likeNumber=68, createdTime=2018-04-07, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2d99395a3, moduleTitle=Lancet：急性冠脉综合征临床显著出血：P2Y12抑制剂+利伐沙班vs阿司匹林, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1a2d99395a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940203, encodeId=573919402031f, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Nature：嘌呤能受体P2Y12与抗血栓药物复合物晶体结构解析, objectType=article, longId=32958, objectId=381f329586f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=381f329586f, replyNumber=0, likeNumber=73, createdTime=2014-07-09, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=381f329586f, moduleTitle=Nature：嘌呤能受体P2Y12与抗血栓药物复合物晶体结构解析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=381f329586f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940202, encodeId=fbfc194020243, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=ACS患者P2Y12受体拮抗剂的选择, objectType=article, longId=27681, objectId=cffc2e681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cffc2e681bd, replyNumber=0, likeNumber=85, createdTime=2014-09-10, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cffc2e681bd, moduleTitle=ACS患者P2Y12受体拮抗剂的选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cffc2e681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

P2Y12

2020-05-29

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识

2018-03-04

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？

2018-06-08

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Am Heart J：血小板功能检测如何指导P2Y12受体抑制剂治疗选择？

2018-04-29

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微

2018-01-01

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Circulation：糖尿病患者血小板表达活化的P2Y12受体

2017-09-03

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Lancet：急性冠脉综合征临床显著出血：P2Y12抑制剂+利伐沙班vs阿司匹林

2018-04-07

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Nature：嘌呤能受体P2Y12与抗血栓药物复合物晶体结构解析

2014-07-09

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

ACS患者P2Y12受体拮抗剂的选择

2014-09-10

科室
- - 订阅+
  - 更多科室
工具
服务